exp3174 has been researched along with candesartan in 27 studies
| Studies (exp3174) | Trials (exp3174) | Recent Studies (post-2010) (exp3174) | Studies (candesartan) | Trials (candesartan) | Recent Studies (post-2010) (candesartan) |
|---|---|---|---|---|---|
| 236 | 29 | 43 | 1,929 | 412 | 589 |
| Protein | Taxonomy | exp3174 (IC50) | candesartan (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 3.2769 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 5.9472 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.0652 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 9 | |
| Adenosine receptor A3 | Homo sapiens (human) | 1.2199 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 3 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.843 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.0652 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.0594 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0405 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.2199 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (33.33) | 18.2507 |
| 2000's | 12 (44.44) | 29.6817 |
| 2010's | 6 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR | 1 |
| De Backer, JP; Fierens, FL; Fraeyman, N; Vanderheyden, PM; Vauquelin, G | 1 |
| Schieffer, B; Schmidt, B | 1 |
| Berellini, G; Cruciani, G; Mannhold, R | 1 |
| Giridhar, R; Murumkar, P; Naik, P; Yadav, MR | 1 |
| Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T | 1 |
| Abad-Santos, F; Cabaleiro, T; López-Rodríguez, R; Novalbos, J; Ochoa, D; Prieto-Pérez, R; Román, M; Talegón, M; Wojnicz, A | 1 |
| Benachour, N; Vanderheyden, PML | 1 |
| Inada, Y; Kohara, Y; Kubo, K; Naka, T; Nishikawa, K; Noda, M; Ojima, M; Sanada, T; Shibouta, Y; Wada, T | 1 |
| Li, XC; Widdop, RE | 1 |
| Harris, PJ; Hiranyachattada, S; Smart, ML | 1 |
| Abrahamsson, T; Adler, G; Brandt-Eliasson, U; Karp, L; Morsing, P; Ohlson, K; Renberg, L; Sjöquist, PO | 1 |
| De Backer, JP; Fierens, FL; Vanderheyden, PM; Vauquelin, G | 1 |
| Garcha, RS; Hughes, AD; Sever, PS | 1 |
| Ardaillou, R; Chansel, D; Llorens-Cortes, C; Vandermeersch, S | 1 |
| Casado, S; Farré, J; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Sánchez de Miguel, L; Zalba, LR | 1 |
| Bassenge, E; Schwemmer, M; Sommer, O | 1 |
| Edvinsson, L; Malmsjö, M; Pantev, E; Stenman, E; Wackenfors, A | 1 |
| Chiba, S; Inada, Y; Nakane, T | 1 |
| Boonstra, PW; Buikema, H; Lübeck, RH; van Buiten, A; van Gilst, WH; van Veldhuisen, DJ; Voors, AA; Wagenaar, LJ | 1 |
| Hunyady, L; Kersemans, V; Le, MT; Szaszák, M; Vanderheyden, PM; Vauquelin, G | 1 |
| Dominiak, P; Häuser, W | 1 |
| Gogonea, C; Karnik, SS; Noda, K; Saad, Y; Takezako, T | 1 |
| Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM | 1 |
| Koyabu, N; Kuwano, M; Murakami, H; Nakamura, T; Ohtani, H; Satoh, H; Sawada, Y; Tsujimoto, M; Uchiumi, T; Ushigome, F; Yamashita, F | 1 |
| Arsenault, J; Cabana, J; Escher, E; Guillemette, G; Lanthier, L; Lavigne, P; Leduc, R; Lehoux, J | 1 |
| Clifford, PS; Davis, MJ; Hill, MA; Hong, K; Hong, Z; Meininger, GA; Sun, Z; Yang, Y; Zhao, G | 1 |
5 review(s) available for exp3174 and candesartan
| Article | Year |
|---|---|
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship | 1996 |
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Growth Hormone; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes; Thromboxane A2 | 2003 |
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan | 2010 |
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
Topics: Angiotensin II Type 1 Receptor Blockers; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Kinetics; Ligands; Protein Binding; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Signal Transduction | 2017 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2004 |
22 other study(ies) available for exp3174 and candesartan
| Article | Year |
|---|---|
Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cattle; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Humans; Inositol Phosphates; Receptors, Angiotensin; Recombinant Proteins; Tetrazoles; Transfection | 1999 |
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Binding Sites; Biphenyl Compounds; Kinetics; Losartan; Models, Molecular; Molecular Conformation; Oxidation-Reduction; Pharmaceutical Preparations; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Structure-Activity Relationship; Tetrazoles | 2005 |
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents | 2011 |
Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
Topics: Alleles; Angiotensin Receptor Antagonists; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Female; Half-Life; Humans; Male; Polymorphism, Genetic; Reference Values; Sex Factors | 2013 |
Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethy
Topics: Adrenal Cortex; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cattle; Imidazoles; In Vitro Techniques; Iodine Radioisotopes; Kinetics; Losartan; Male; Muscle Contraction; Muscle, Smooth, Vascular; Prodrugs; Protein Binding; Rabbits; Rats; Rats, Sprague-Dawley; Substrate Specificity; Tetrazoles | 1993 |
Angiotensin type 1 receptor antagonists CV-11974 and EXP 3174 cause selective renal vasodilatation in conscious spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Imidazoles; Losartan; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Tetrazoles; Vasodilation | 1996 |
Effects of angiotensin II receptor blockade on proximal fluid uptake in the rat kidney.
Topics: Absorption; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Body Fluids; Dose-Response Relationship, Drug; Imidazoles; Kidney Tubules, Proximal; Losartan; Male; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 1999 |
Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Proteins; Female; Humans; Imidazoles; In Vitro Techniques; Irbesartan; Kinetics; Losartan; Male; Muscle Contraction; Muscle, Smooth, Vascular; Portal Vein; Rabbits; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 1999 |
Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Binding, Competitive; Biphenyl Compounds; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Recombinant Proteins; Tetrazoles | 1999 |
Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Arteries; Benzimidazoles; Biphenyl Compounds; Endothelium, Vascular; Humans; Imidazoles; Losartan; Muscle Tonus; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Vasoconstrictor Agents | 1999 |
Effects of angiotensin II and antagonists on AT(1) receptor expression in mesangial cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Dexamethasone; Dose-Response Relationship, Drug; Gene Expression Regulation; Glomerular Mesangium; Imidazoles; Losartan; Male; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Tetrazoles | 1999 |
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibodies, Monoclonal; Benzimidazoles; Benzoates; Binding, Competitive; Biphenyl Compounds; Blood Platelets; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Platelet Activation; Pyridines; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Telmisartan; Tetrazoles; Thromboxane A2; Time Factors; Valine; Valsartan | 2000 |
Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.
Topics: Angiotensin Receptor Antagonists; Animals; Arachidonic Acids; Benzimidazoles; Biphenyl Compounds; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imidazoles; Losartan; Phospholipases A; Phospholipases A2; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Thromboxane; Renin-Angiotensin System; Signal Transduction; Tetrazoles; Thromboxane A2 | 2001 |
Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Base Sequence; Benzimidazoles; Biphenyl Compounds; Coronary Vessels; Culture Techniques; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Losartan; Male; Middle Aged; Molecular Sequence Data; Probability; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Valine; Valsartan; Vasoconstriction | 2002 |
Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Chlorocebus aethiops; COS Cells; Dose-Response Relationship, Drug; Humans; Imidazoles; In Vitro Techniques; Liver; Losartan; Membranes; Oligopeptides; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Thiadiazoles; Time Factors; Transfection | 2002 |
Functional antagonism of different angiotensin II type I receptor blockers in human arteries.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Humans; Imidazoles; In Vitro Techniques; Losartan; Mammary Arteries; Muscle Contraction; Muscle, Smooth, Vascular; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2002 |
Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors.
Topics: Alanine; Amino Acid Substitution; Animals; Antihypertensive Agents; Aspartic Acid; Benzimidazoles; Biphenyl Compounds; CHO Cells; Cricetinae; Humans; Imidazoles; Kinetics; Losartan; Mutagenesis, Site-Directed; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Transfection; Tritium | 2003 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Placebos; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Time Factors; Valine; Valsartan | 2003 |
"Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists.
Topics: Amino Acid Sequence; Animals; Benzimidazoles; Binding, Competitive; Biphenyl Compounds; Cell Membrane; COS Cells; Dose-Response Relationship, Drug; Imidazoles; Kinetics; Ligands; Losartan; Models, Chemical; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Peptides; Protein Conformation; Rats; Receptor, Angiotensin, Type 1; Temperature; Tetrazoles; Time Factors | 2004 |
Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4.
Topics: Acetates; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biological Transport; Biphenyl Compounds; Blotting, Western; Cell Line; Chromones; Cyclopropanes; Dose-Response Relationship, Drug; Estrone; Humans; Imidazoles; Indoles; Leukotriene Antagonists; Losartan; Molecular Structure; Organic Anion Transporters, Sodium-Independent; Phenylcarbamates; Quinolines; Structure-Activity Relationship; Sulfides; Sulfonamides; Tetrazoles; Tosyl Compounds; Transfection; Tritium; Valine; Valsartan | 2006 |
A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.
Topics: Alanine; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Chlorocebus aethiops; COS Cells; Humans; Imidazoles; Inositol Phosphates; Irbesartan; Losartan; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Telmisartan; Tetrazoles; Threonine; Valine; Valsartan | 2010 |
Mechanical activation of angiotensin II type 1 receptors causes actin remodelling and myogenic responsiveness in skeletal muscle arterioles.
Topics: Abdominal Muscles; Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterioles; Benzimidazoles; Biphenyl Compounds; Captopril; Cells, Cultured; Diglycerides; Imidazoles; Indoles; Losartan; Male; Maleimides; Muscle Development; Muscle Fibers, Skeletal; Pressure; Protein Kinase C; Pyridines; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Vasoconstriction; Vasoconstrictor Agents | 2016 |